Study of effect of teneligliptin versus glimepiride on tumor necrosis factor alpha (TNF- Î±) and high sensitivity C- reactive protein (hs-CRP) in type 2 diabetes mellitus patients treated with metformin. - TNF/CRP

MALEHA BUT0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Body mass index (BMI) more than 25 kg/m2
•2.All type 2 DM patients with a history of diabetes for the past 1 to 3 years
•3.Type 2 diabetics with fasting blood sugar more than 126mg/dl and glycosylated hemoglobin (HbA1c) between 7.0 to 10.0 % before enrollment.
•4.All type 2 DM patients, who are on stable dose of metformin (up to 2500mg/day) for the past 12 weeks.
•5.All patients naive to teneligliptin and glimepiride.
•6.All patients willing to give consent to participate in the study.

•1.Uncontrolled hypertension (systolic BP more than or equal to 180 mmHg and diastolic BP more than or equal to 100 mmHg)
•2.Uncontrolled diabetes (HbA1c more than or equal to 10.0 %).
•3.Patientâ??s having serum creatinine (SCr) levels more than or equal to 2mg/dL.
•4.Patients with hepatic impairment (AST and ALT levels more than or equal to 3 times the upper limit).
•5.Serum triglycerides more than or equal to 500mg/dl.
•6.Pregnant females and lactating mothers
•7.History of hypersensitivity to study drugs.
•8.History of taking non steroidal anti-inflammatory drugs or any other drugs that affect the study parameters.
•9.Patients on any other herbal and dietary supplements.

发起方

MALEHA BUT